Loading
A phase 3 trial of Magrolimab, Venetoclax, Azacitidine, Cytarabine, Daunorubicin and Idarubicin in Acute myeloid leukaemia, run by Gilead Sciences, recorded as terminated on the registry.
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated is a phase 3 interventional study registered as NCT04778397 by Gilead Sciences, with 258 participants recorded, started 2021-07-01 and due to reach its primary completion in 2024-03-25. Interventions recorded: Magrolimab, Venetoclax, Azacitidine, Cytarabine, Daunorubicin, Idarubicin, Steroidal Eye Drops. Conditions recorded: Acute Myeloid Leukemia.
Linked to the drug Magrolimab because the registry names it among its interventions and Acute myeloid leukaemia among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
258 enrolled.
95% CI 3.6 to 6.0; Figures from the ClinicalTrials.gov results section (first posted 2025-02-05), not from a publication · 95% CI 4.8 to 8.1
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Survival (OS) in Participants Appropriate for Non-intensive Therapyprimary | Magrolimab + Azacitidine (Non-Intensive Therapy) | 101 | 4.4 months | 1.132 (0.783 to 1.637) | 0.5070 | link |
| Control Arm: Venetoclax + Azacitidine (Non-Intensive Therapy) | 104 | 6.6 months |
Shares Magrolimab, Gilead Sciences (incl. Kite), Azacitidine, Venetoclax and the tag pipeline.
Shares Daunorubicin, Cytarabine, Azacitidine, Venetoclax and the tag pipeline.
Shares Magrolimab, Gilead Sciences (incl. Kite), Azacitidine and the tag pipeline.
Shares Daunorubicin, Cytarabine, Azacitidine, Venetoclax and the tag pipeline.
Shares Cytarabine, Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.
Shares Idarubicin, Daunorubicin, Cytarabine, Acute myeloid leukaemia and the tag pipeline.
Shares Daunorubicin, Cytarabine, Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia and the tag pipeline.